Four weeks of non-invasive DIFS™ neurostimulation delivers meaningful attention gains alongside objective brain imaging changesHOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a new peer-reviewed clinical study in Molecular Psychiatry demonstrating Nexalin’s Deep Intracranial Frequency Stimulation (DIFS™) technology pro ...